Role of Perfusion CT in Pancreatic Cancer

Browse trials for

• Adenocarcinoma 2,004
• Pancreatic Neoplasms 3,235
• Carcinoma, Neuroendocrine 236

Keywords

• CT
• pancreas adenocarcinoma
• RECIST
• perfusion

Adenocarcinoma

2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.

This study's enrollment of 48 is below the median of 153 across 332 observational studies indexed under Adenocarcinoma.

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Study population

Groups and cohorts

• Resectable pancreas cancer

  patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration

  Drug: iopromide · Procedure: CT

• Locally advanced Pancreas cancer

  Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.

  Drug: iopromide · Procedure: CT

Interventions

• Drugiopromide

  1. iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation. 2. In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle. 3. iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight\[BW\] \<50kg) or 35 mL (50kg ≤BW \<70kg) or 40 mL (70 kg≤BW \<90kg) or 50 mL (90≤BW), followed by saline infusion (30mL). 4. Injection rate is as follows; 6.0mL/sec if BW is \<50kg, 7.0 mL/sec if BW is 50kg≤and \<70kg, 8.0 mL/sec if BW is 70≤and\<90kg and 9.0mL/sec if BW is 90kg≤.

  Also known as: Ultravist® (370mgI/mL)

• ProcedureCT

  1. Perfusion CT will be performed by using a 320 channel MDCT 2. Patients are requested for fasting for at least 8 hours before CT scan. 3. Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan. 4. Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion. 5. During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds. 6. ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose.

Primary outcomes

1. Evaluation of the correlation between the initial perfusion parameters of the tumor and response of the chemotherapy

   Initial perfusion parameters (blood volume, blood flow and permeability) are compared between CTx-responder and non-responders after 6 cycle of the scheduled chemotherapy, using RECIST 1.1 criteria.

   Time frame: after 6 cycles of the planned chemotherapy

Secondary outcomes

1. Correlation between change of perfusion parameters and the chemotherapy response

   Perfusion parameters (blood volume, blood flow, and permeability) change between initial perfusion CT and second perfusion CT (which is taken after 2 cycle of the CTx) are compared between CTx-responder and non-responder after finishing 6 cycles of CTx according to RECIST 1.1 criteria.

   Time frame: after 6 cycles of the chemotherapy

2. Perfusion parameters among different pancreas tumors

   Perfusion parameters (blood volume, blood flow and permeability) are compared among the different types of the pancreas tumors to investigate perfusion parameters can help characterization of the tumors.

   Time frame: within 2 months after finishing enrollment

3. comparison of perfusion parameters among the pancreas tumors and parenchyma

   blood volume, blood flow and permeability are compared between the tumor and the pancreas parenchyma.

   Time frame: within three weeks before pancreas tumor surgery

Individual participant data

Plan to share: No